论文信息 - Nivolumab for metastatic renal cell carcinoma (mRCC): Results of a randomized, dose-ranging phase II trial. - 字舞流文

Nivolumab for metastatic renal cell carcinoma (mRCC): Results of a randomized, dose-ranging phase II trial.

R. Motzer | M. Harrison | E. Plimack | B. Redman | B. Rini | T. Kuzel | H. Drabkin | U. Vaishampayan | D. McDermott | K. Margolin | A. Lambert | S. George | H. Hammers | I. Waxman | T. Logan